QA: Bellerophon Therapeutics Inc. in us_pharma/2019

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001600132_2020_Bellerophon_Therapeutics_Inc.pdf

Logs

warning Missing logo subcommand.report {}
info Failed to set obs_EconomicCapitalRatio industry.us_generic {'reason': "KeyError('0001600132')"}
info Added remainder_ComprehensiveNetIncome directly from 10K industry.us_generic {}

Graph

Absolute values for 0001600132, Bellerophon Therapeutics Inc.

  xvar xval
0 AssetsCurrent 10,382,000
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 316,000
3 remainder_Assets 2,410,000
4 LiabilitiesCurrent 7,584,000
5 LiabilitiesNoncurrent 1,659,000
6 remainder_Liabilities 274,000
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 6,441,000
9 ResearchAndDevelopmentExpense 11,032,000
10 remainder_Expenses -3,783,000
11 remainder_Revenues 0
12 remainder_NetIncome 397,000
13 remainder_ComprehensiveNetIncome 0
  yvar yval
0 Assets 13,108,000
1 Liabilities 9,517,000
2 Expenses 13,690,000
3 Revenues 0
4 StockholdersEquity 3,591,000
5 NetIncome -13,293,000
6 ComprehensiveNetIncome -13,293,000
7 BaseVar 18,356,000
8 EconomicCapitalRatio -0.629

Edgar->Model Mapping

Feature Distribution

Change over Time